Minerva Neurosciences forms scientific advisory board

Mon, 01 Jun 2026 16:05:28 -0400

Minerva Neurosciences Inc. (NASDAQ: NERV) announced the establishment of a Scientific Advisory Board to guide the development of its experimental drug roluperidone and broader research strategy, according to a company statement.

The board includes eight members with expertise in psychiatry and neuroscience, including company executives and external researchers from institutions such as the University of Miami, King's College London, and the University of Arkansas for Medical Sciences.

The advisory board will provide guidance on the company's ongoing Phase 3 confirmatory trial of roluperidone for treating negative symptoms of schizophrenia. The global trial, designated NCT07565428, plans to enroll approximately 380 adults aged 18-55

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Mon, 01 Jun 2026 16:05:00 -0400

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy

BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company’s PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience.

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Mon, 01 Jun 2026 16:05:00 -0400

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy

Form 8-K Minerva Neurosciences, For: May 27

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558148.html

Form 8-K Minerva Neurosciences, For: May 27

Wed, 27 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26558148.html

Form 424B5 Minerva Neurosciences,

Wed, 27 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26558053.html

Form 424B5 Minerva Neurosciences,

Wed, 27 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260527/26558053.html

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Mon, 18 May 2026 16:05:00 -0400

BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

2026 Jefferies Global Healthcare Conference
Format:	Fireside chat
Day/Time:	Thursday, June 4 at 4:20 PM ET
Webcast:	Link here

If you are interested in meeting with the Minerva team during the

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Mon, 18 May 2026 16:05:00 -0400

2026 Jefferies Global Healthcare Conference
Format:	Fireside chat
Day/Time:	Thursday, June 4 at 4:20 PM ET
Webcast:	Link here

If you are interested in meeting with the Minerva team during the

Form SCHEDULE 13G Minerva Neurosciences, Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 11:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26502338.html

Form SCHEDULE 13G Minerva Neurosciences, Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 11:44:00 -0400

si-local-file:///var/storage/secattach/20260515/26502338.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26498851.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26498851.html

Minerva Neurosciences (NERV) Misses Q1 EPS by 4c

Tue, 05 May 2026 10:18:52 -0400

Minerva Neurosciences (NASDAQ: NERV) reported Q1 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Minerva Neurosciences (NERV) click here.

Form 10-Q Minerva Neurosciences, For: Mar 31

Tue, 05 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26430592.html

Form 10-Q Minerva Neurosciences, For: Mar 31

Tue, 05 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260505/26430592.html

Form 8-K Minerva Neurosciences, For: May 05

Tue, 05 May 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260505/26430397.html

Form 8-K Minerva Neurosciences, For: May 05

Tue, 05 May 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260505/26430397.html

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Tue, 05 May 2026 08:00:00 -0400

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened

Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine